About Acyl-CoA:lysophosphatidylglycerol acyltransferase 1
Acyl-CoA:lysophosphatidylglycerol acyltransferase 1 (LPGAT1) is a protein
from Homo sapiens identified by UniProt accession
Q92604, 370 residues long.
MolForge cross-references it against 0 known binders and
67 disease associations.
Target properties
| Protein name | Acyl-CoA:lysophosphatidylglycerol acyltransferase 1 |
| UniProt accession | Q92604 |
| Gene | LPGAT1 |
| Organism | Homo sapiens |
| Length | 370 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (67)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.53
- urate measurement · score 0.20
- fatty acid measurement · score 0.19
- breast adenocarcinoma · score 0.18
- unipolar depression · score 0.17
- mean reticulocyte volume · score 0.15
- self reported educational attainment · score 0.12
- Gorham-Stout disease · score 0.07
- MEGDEL syndrome · score 0.06
- Familial exudative vitreoretinopathy · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q92604-F1 | alphafold | PREDICTED | 92.73 | — |
Amino-acid sequence (370 residues)
MAITLEEAPW LGWLLVKALM RFAFMVVNNL VAIPSYICYV IILQPLRVLD SKRFWYIEGI MYKWLLGMVA SWGWYAGYTV MEWGEDIKAV SKDEAVMLVN HQATGDVCTL MMCLQDKGLV VAQMMWLMDH IFKYTNFGIV SLVHGDFFIR QGRSYRDQQL LLLKKHLENN YRSRDRKWIV LFPEGGFLRK RRETSQAFAK KNNLPFLTNV TLPRSGATKI ILNALVAQQK NGSPAGGDAK ELDSKSKGLQ WIIDTTIAYP KAEPIDIQTW ILGYRKPTVT HVHYRIFPIK DVPLETDDLT TWLYQRFVEK EDLLSHFYET GAFPPSKGHK EAVSREMTLS NLWIFLIQSF AFLSGYMWYN IIQYFYHCLF
Explore Acyl-CoA:lysophosphatidylglycerol acyltransferase 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets